FOLH1 and neoplasm: Despite having analyzed differences in tumor dose between responders and non-responders according to RECIST 1.1 criteria, the interpretation of these results is highly limited due to the very low number of responders (2/30 patients, 7%), which once again emphasizes that RECIST 1.1 does not represent the best response criteria after PSMA-RLT.